15 Trademark Results found for "*BEQ"

Also try searching for:

BEQ*

Details	Status	Class/Description
TOBEQ G2S Tobeq Inc. 2251205 12 Apr 2023	REGISTERED on 22 Nov 2024	Tool boxes of metal,Hand tools; hand-operated lifting jacks; manually ... Class 006 Class 006 Metal Products Tool boxes of metal Class 008 Class 008 Hand Tool Products Hand tools; hand-operated lifting jacks; manually operated jacks
VOCINBEQ GLOBAL BLOOD THERAPEUTICS INC. 2210021 15 Aug 2022	REGISTERED on 25 Apr 2024	Pharmaceutical preparations for the treatment of vaso-occlusive crisis... Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for the treatment of vaso-occlusive crisis; pharmaceutical preparations for the treatment of hematological disorders such as sickle cell disease; pharmaceutical preparations for the treatment of hypoxic and hypoxemic conditions.
XTINBEQ CELGENE CORPORATION 2064591 18 Nov 2020	REGISTERED on 5 Feb 2024	Pharmaceutical preparations for human use for the treatment and preven... Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies.
ZACUBEQ CELGENE CORPORATION 2064554 17 Nov 2020	ABANDONED SECTION 36 on 11 Jan 2024	Pharmaceutical preparations for human use. Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use.
VYTRUBEQ CELGENE CORPORATION 2064552 17 Nov 2020	ABANDONED SECTION 36 on 11 Jan 2024	Pharmaceutical preparations for human use. Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use.
XALTUBEQ CELGENE CORPORATION 2064553 17 Nov 2020	REGISTERED on 5 Feb 2024	Pharmaceutical preparations for human use for the treatment and preven... Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies.
EXTRUBEQ CELGENE CORPORATION 2064557 17 Nov 2020	ABANDONED SECTION 36 on 11 Jan 2024	Pharmaceutical preparations for human use. Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use.
BONCEBEQ CELGENE CORPORATION 2058325 19 Oct 2020	REGISTERED on 12 Feb 2024	Pharmaceutical preparations for human use for the treatment and preven... Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies.
MYDURIBEQ CELGENE CORPORATION 2058236 16 Oct 2020	ABANDONED SECTION 36 on 29 Dec 2023	Pharmaceutical preparations for human use Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use
ADURIBEQ CELGENE CORPORATION 2049676 3 Sept 2020	REGISTERED on 24 Nov 2023	Pharmaceutical preparations for human use for the treatment and preven... Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as antiinfectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies.

REGISTERED

on 22 Nov 2024

TOBEQ

G2S Tobeq Inc.

2251205 · 12 Apr 2023

006

008

Tool boxes of metal,Hand tools; hand-operated lifting jacks; manually ...

REGISTERED

on 25 Apr 2024

VOCINBEQ

GLOBAL BLOOD THERAPEUTICS INC.

2210021 · 15 Aug 2022

005

Pharmaceutical preparations for the treatment of vaso-occlusive crisis...

REGISTERED

on 5 Feb 2024

XTINBEQ

CELGENE CORPORATION

2064591 · 18 Nov 2020

005

Class 005

Pharmaceutical Products

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies.

Pharmaceutical preparations for human use for the treatment and preven...

ABANDONED SECTION 36

on 11 Jan 2024

ZACUBEQ

CELGENE CORPORATION

2064554 · 17 Nov 2020

005

Pharmaceutical preparations for human use.

ABANDONED SECTION 36

on 11 Jan 2024

VYTRUBEQ

CELGENE CORPORATION

2064552 · 17 Nov 2020

005

Pharmaceutical preparations for human use.

REGISTERED

on 5 Feb 2024

XALTUBEQ

CELGENE CORPORATION

2064553 · 17 Nov 2020

005

Class 005

Pharmaceutical Products

Pharmaceutical preparations for human use for the treatment and preven...

ABANDONED SECTION 36

on 11 Jan 2024

EXTRUBEQ

CELGENE CORPORATION

2064557 · 17 Nov 2020

005

Pharmaceutical preparations for human use.

REGISTERED

on 12 Feb 2024

BONCEBEQ

CELGENE CORPORATION

2058325 · 19 Oct 2020

005

Class 005

Pharmaceutical Products

Pharmaceutical preparations for human use for the treatment and preven...

ABANDONED SECTION 36

on 29 Dec 2023

MYDURIBEQ

CELGENE CORPORATION

2058236 · 16 Oct 2020

005

Pharmaceutical preparations for human use

REGISTERED

on 24 Nov 2023

ADURIBEQ

CELGENE CORPORATION

2049676 · 3 Sept 2020

005

Class 005

Pharmaceutical Products

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as antiinfectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies.

Pharmaceutical preparations for human use for the treatment and preven...

Owners

Celgene corporation (8)

Merck kgaa (2)

Franchises bo-beq inc. (1)

G2s tobeq inc. (1)

Global blood therapeutics inc. (1)

Mbeq llc (1)

Plethora solutions holdings plc (1)

Categories

Class 5 (11)

Class 6 (1)

Class 8 (1)

Class 41 (1)

Class 43 (1)

Class 44 (1)

Correspondents

Gowling wlg (canada) llp (8)

Smart & biggar ip agency co. (2)

Borden ladner gervais llp (1)

Canyon ip inc. (1)

Smart & biggar lp (1)

Display

List View

Grid View

Apply for Trademark

Select countries to protect your logo Trademark

Trademark Name

Country Selected

Canada

C$500/ 1 class + gov fee

United States

C$137/ 1 class + gov fee

Canada

C$500/ 1 class + gov fee

Mexico

C$691/ 1 class + gov fee

European Union

C$969/ 1 class + gov fee

China

C$691/ 1 class + gov fee

South Korea

C$967/ 1 class + gov fee

Japan

C$1,106/ 1 class + gov fee

India

C$137/ 1 class + gov fee

United Kingdom

C$691/ 1 class + gov fee

Australia

C$414/ 1 class + gov fee

Israel

C$967/ 1 class + gov fee

United Arab Emirates

C$967/ 1 class + gov fee

New Zealand

C$967/ 1 class + gov fee

Brazil

C$691/ 1 class + gov fee

Taiwan

C$1,106/ 1 class + gov fee

Ukraine

C$1,106/ 1 class + gov fee

Indonesia

C$967/ 1 class + gov fee

South Africa

C$691/ 1 class + gov fee

Singapore

C$1,106/ 1 class + gov fee

Saudi Arabia

C$1,106/ 1 class + gov fee

Afghanistan

C$1,106/ 1 class + gov fee

Algeria

C$1,106/ 1 class + gov fee

Argentina

C$552/ 1 class + gov fee

Austria

C$1,244/ 1 class + gov fee

Bahrain

C$967/ 1 class + gov fee

Bangladesh

C$829/ 1 class + gov fee

Benelux

C$1,382/ 1 class + gov fee

Bhutan

C$1,244/ 1 class + gov fee

Bolivia

C$1,106/ 1 class + gov fee

Botswana

C$1,797/ 1 class + gov fee

British Virgin Islands

C$1,659/ 1 class + gov fee

Bulgaria

C$1,106/ 1 class + gov fee

Cambodia

C$1,106/ 1 class + gov fee

Chile

C$691/ 1 class + gov fee

Colombia

C$967/ 1 class + gov fee

Congo

C$1,659/ 1 class + gov fee

Costa Rica

C$1,244/ 1 class + gov fee

Croatia

C$1,244/ 1 class + gov fee

Cyprus

C$1,382/ 1 class + gov fee

Czech Republic

C$1,244/ 1 class + gov fee

Denmark

C$1,106/ 1 class + gov fee

Curacao

C$1,659/ 1 class + gov fee

Macau

C$967/ 1 class + gov fee

Dominican Republic

C$1,244/ 1 class + gov fee

Aruba

C$1,659/ 1 class + gov fee

Greenland

C$1,106/ 1 class + gov fee

Ecuador

C$1,106/ 1 class + gov fee

Egypt

C$967/ 1 class + gov fee

El Salvador

C$1,106/ 1 class + gov fee

Ethiopia

C$1,521/ 1 class + gov fee

France

C$1,244/ 1 class + gov fee

Gaza

C$1,106/ 1 class + gov fee

Germany

C$1,244/ 1 class + gov fee

Greece

C$1,106/ 1 class + gov fee

Guatemala

C$1,244/ 1 class + gov fee

Haiti

C$1,244/ 1 class + gov fee

Honduras

C$1,244/ 1 class + gov fee

Hong Kong (SAR)

C$1,244/ 1 class + gov fee

Hungary

C$1,521/ 1 class + gov fee

Iraq

C$2,074/ 1 class + gov fee

Italy

C$1,244/ 1 class + gov fee

Jordan

C$1,106/ 1 class + gov fee

Kazakhstan

C$1,106/ 1 class + gov fee

Kenya

C$1,244/ 1 class + gov fee

Kuwait

C$1,106/ 1 class + gov fee

Laos

C$967/ 1 class + gov fee

Lebanon

C$1,382/ 1 class + gov fee

Lesotho

C$1,659/ 1 class + gov fee

Libya

C$1,244/ 1 class + gov fee

Madrid Protocol (WIPO)

C$2,766/ 1 class + gov fee

Malawi

C$1,521/ 1 class + gov fee

Malaysia

C$967/ 1 class + gov fee

Maldives

C$1,382/ 1 class + gov fee

Morocco

C$1,382/ 1 class + gov fee

Mozambique

C$1,244/ 1 class + gov fee

Myanmar

C$1,106/ 1 class + gov fee

Namibia

C$1,106/ 1 class + gov fee

Nepal

C$967/ 1 class + gov fee

Nicaragua

C$1,244/ 1 class + gov fee

Norway

C$1,244/ 1 class + gov fee

Oman

C$1,521/ 1 class + gov fee

Pakistan

C$1,106/ 1 class + gov fee

Panama

C$1,244/ 1 class + gov fee

Paraguay

C$1,244/ 1 class + gov fee

Peru

C$1,106/ 1 class + gov fee

Philippines

C$1,244/ 1 class + gov fee

Poland

C$691/ 1 class + gov fee

Portugal

C$1,244/ 1 class + gov fee

Puerto Rico

C$1,244/ 1 class + gov fee

Qatar

C$1,106/ 1 class + gov fee

Romania

C$1,244/ 1 class + gov fee

Serbia

C$1,244/ 1 class + gov fee

Slovakia

C$1,244/ 1 class + gov fee

Spain

C$1,244/ 1 class + gov fee

Sri Lanka

C$967/ 1 class + gov fee

Swaziland

C$1,797/ 1 class + gov fee

Sweden

C$1,106/ 1 class + gov fee

Switzerland

C$1,244/ 1 class + gov fee

Thailand

C$1,106/ 1 class + gov fee

Tunisia

C$1,244/ 1 class + gov fee

Turkey

C$1,106/ 1 class + gov fee

Uganda

C$967/ 1 class + gov fee

United Republic of Tanzania

C$967/ 1 class + gov fee

Uruguay

C$1,106/ 1 class + gov fee

Venezuela

C$1,244/ 1 class + gov fee

Vietnam

C$1,106/ 1 class + gov fee

West Bank, Palestine

C$1,106/ 1 class + gov fee

Yemen

C$2,351/ 1 class + gov fee

Albania

C$1,244/ 1 class + gov fee

Andorra

C$1,244/ 1 class + gov fee

Angola

C$1,797/ 1 class + gov fee

Antigua and Barbuda

C$1,659/ 1 class + gov fee

Armenia

C$1,106/ 1 class + gov fee

Azerbaijan

C$1,106/ 1 class + gov fee

Bahamas

C$1,936/ 1 class + gov fee

Barbados

C$1,797/ 1 class + gov fee

Belgium

C$1,382/ 1 class + gov fee

Belize

C$1,797/ 1 class + gov fee

Benin

C$1,106/ 1 class + gov fee

Bosnia and Herzegovina

C$1,382/ 1 class + gov fee

Brunei

C$1,797/ 1 class + gov fee

Burkina Faso

C$1,106/ 1 class + gov fee

Burundi

C$1,659/ 1 class + gov fee

Cabo Verde

C$1,244/ 1 class + gov fee

Cameroon

C$1,106/ 1 class + gov fee

Central African Republic (CAR)

C$1,106/ 1 class + gov fee

Chad

C$1,106/ 1 class + gov fee

Comoros

C$1,106/ 1 class + gov fee

Cote d'Ivoire

C$1,106/ 1 class + gov fee

Czechia

C$1,382/ 1 class + gov fee

Djibouti

C$1,659/ 1 class + gov fee

Dominica

C$1,797/ 1 class + gov fee

Equatorial Guinea

C$1,106/ 1 class + gov fee

Eritrea

C$1,382/ 1 class + gov fee

Estonia

C$1,797/ 1 class + gov fee

Eswatini

C$1,797/ 1 class + gov fee

Fiji

C$1,244/ 1 class + gov fee

Finland

C$967/ 1 class + gov fee

Gabon

C$1,106/ 1 class + gov fee

Gambia

C$1,244/ 1 class + gov fee

Georgia

C$1,106/ 1 class + gov fee

Ghana

C$1,382/ 1 class + gov fee

Grenada

C$1,797/ 1 class + gov fee

Guinea

C$1,106/ 1 class + gov fee

Guinea-Bissau

C$1,106/ 1 class + gov fee

Guyana

C$1,797/ 1 class + gov fee

Iceland

C$1,797/ 1 class + gov fee

Ireland

C$1,244/ 1 class + gov fee

Jamaica

C$1,659/ 1 class + gov fee

Kiribati

C$1,382/ 1 class + gov fee

Kosovo

C$1,244/ 1 class + gov fee

Kyrgyzstan

C$1,244/ 1 class + gov fee

Latvia

C$967/ 1 class + gov fee

Liberia

C$1,382/ 1 class + gov fee

Liechtenstein

C$1,382/ 1 class + gov fee

Lithuania

C$967/ 1 class + gov fee

Luxembourg

C$1,382/ 1 class + gov fee

Madagascar

C$1,382/ 1 class + gov fee

Mali

C$1,106/ 1 class + gov fee

Malta

C$829/ 1 class + gov fee

Marshall Islands

C$1,382/ 1 class + gov fee

Mauritania

C$1,106/ 1 class + gov fee

Mauritius

C$1,382/ 1 class + gov fee

Micronesia

C$1,382/ 1 class + gov fee

Moldova

C$1,382/ 1 class + gov fee

Monaco

C$1,936/ 1 class + gov fee

Mongolia

C$829/ 1 class + gov fee

Montenegro

C$1,244/ 1 class + gov fee

Nauru

C$1,382/ 1 class + gov fee

Netherlands

C$1,382/ 1 class + gov fee

Niger

C$1,106/ 1 class + gov fee

Nigeria

C$552/ 1 class + gov fee

North Macedonia

C$1,244/ 1 class + gov fee

Palau

C$1,382/ 1 class + gov fee

Palestine

C$1,382/ 1 class + gov fee

Papua New Guinea

C$1,106/ 1 class + gov fee

Rwanda

C$1,382/ 1 class + gov fee

Saint Kitts and Nevis

C$1,797/ 1 class + gov fee

Saint Lucia

C$1,797/ 1 class + gov fee

Saint Vincent and the Grenadines

C$1,797/ 1 class + gov fee

Samoa

C$1,659/ 1 class + gov fee

San Marino

C$1,382/ 1 class + gov fee

Sao Tome and Principe

C$1,382/ 1 class + gov fee

Senegal

C$1,106/ 1 class + gov fee

Seychelles

C$1,382/ 1 class + gov fee

Sierra Leone

C$1,382/ 1 class + gov fee

Slovenia

C$1,244/ 1 class + gov fee

Solomon Islands

C$1,382/ 1 class + gov fee

Somalia

C$1,382/ 1 class + gov fee

South Sudan

C$1,382/ 1 class + gov fee

Suriname

C$2,212/ 1 class + gov fee

Tajikistan

C$1,106/ 1 class + gov fee

Tanzania

C$967/ 1 class + gov fee

Timor-Leste

C$1,382/ 1 class + gov fee

Togo

C$1,106/ 1 class + gov fee

Tonga

C$1,797/ 1 class + gov fee

Trinidad and Tobago

C$1,659/ 1 class + gov fee

Turkmenistan

C$1,106/ 1 class + gov fee

Tuvalu

C$1,382/ 1 class + gov fee

Uzbekistan

C$967/ 1 class + gov fee

Vanuatu

C$1,659/ 1 class + gov fee

Zambia

C$1,244/ 1 class + gov fee

Zimbabwe

C$1,244/ 1 class + gov fee

OAPI

C$1,244/ 1 class + gov fee

ARIPO

C$1,382/ 1 class + gov fee

Page 1 of 2